The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
Status:
Unknown status
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
The present study is an exploratory study. Patients who meeting the enrollment conditions for
relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells.
The research with the open-label, single arm running control methods in order to initially
observe the safety, tolerability, and cellular pharmacokinetics of CD20-CART cell drugs.